
|Articles|April 16, 2014
- Melanoma (Issue 2)
- Volume 2
- Issue 1
An Overview of Immune Checkpoint Blockade
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, explains immune checkpoint blockade.
Advertisement
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, explains immune checkpoint blockade.
Read more about immunotherapies and combination strategies for the treatment of melanoma > >
Articles in this issue
almost 12 years ago
Sequencing Strategies in Treating Patients With Melanomaalmost 12 years ago
Research Into Newer Agents Under Way for NRAS Melanomaalmost 12 years ago
New Crop of Combination Strategies Growing for Melanomaalmost 12 years ago
Approaches to Sequencing in Melanoma: Three Melanoma Specialists Weigh Inalmost 12 years ago
In Practice: Combination Therapies in Metastatic Melanomaalmost 12 years ago
New and Emerging Therapies for Metastatic Melanomaalmost 12 years ago
Mutation Tests in Melanoma Crucial for Treatmentalmost 12 years ago
What’s Next With Next-Generation BRAF Inhibitors?Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















